Amedeo Smart

Free Medical Literature Service

 

Amedeo

Peptic Ulcer
  Free Subscription

Articles published in
Helicobacter
    January 2026
  1. PARRA P, Nyssen OP, Gisbert JP
    Non-Bismuth Quadruple Concomitant Treatment for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Helicobacter. 2026;31:e70099.
    >> Share

  2. STERBENC A, Vratanar B, Mojskerc EM, Homan M, et al
    An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7-Day Triple Therapy With Bismuth Versus 14-Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents.
    Helicobacter. 2026;31:e70103.
    >> Share

  3. EL-AZAB G, Abdel Salam S, Moustafa E, Abuoelhassan A, et al
    Efficacy and Safety of Levofloxacin- Versus Moxifloxacin-Based Nitazoxanide Quadruple Therapy as Second-Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial.
    Helicobacter. 2026;31:e70104.
    >> Share

  4. PATIL S, Sarkar S, Jobby R, Yu S, et al
    Drug Repurposing Identifies Natamycin and Avacopan as Urease-Targeted Therapeutic Candidates Against Helicobacter pylori.
    Helicobacter. 2026;31:e70094.
    >> Share

  5. TEPES B, Bric TK, Oblak M, Zavrsnik J, et al
    EUROHELICAN-Accelerating Gastric Cancer Reduction Through Helicobacter pylori Eradication.
    Helicobacter. 2026;31:e70097.
    >> Share

  6. PARK JY, Hong SJ, Choi IJ, Baik GH, et al
    Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.
    Helicobacter. 2026;31:e70106.
    >> Share

  7. WEI S, Huang Z, Xiong H, Wu J, et al
    Efficacy and Safety of Keverprazan-Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial.
    Helicobacter. 2026;31:e70100.
    >> Share

  8. NYSSEN OP, Ortega GJ, Jonaitis L, Perez-Aisa A, et al
    Long-Term Effect of Macrolides on Helicobacter pylori Eradication: Data From the European Registry on Helicobacter pylori Management (Hp-EuReg).
    Helicobacter. 2026;31:e70107.
    >> Share

    November 2025

  9. Correction to "Letter to the Editor: 'Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection'".
    Helicobacter. 2025;30:e70088.
    >> Share

  10. MATSUMOTO C, Saito H, Nishikawa Y, Saito Y, et al
    Survey on Awareness of Helicobacter pylori and Gastric Cancer in the Japanese Population Using an Internet Survey.
    Helicobacter. 2025;30:e70089.
    >> Share

  11. HAN Q, Zu M, Du S, Guo Y, et al
    Different Doses of Ilaprazole for Dual Therapy Versus Bismuth-Quadruple Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Helicobacter. 2025;30:e70086.
    >> Share

  12. AYE TT, Ni N, May TT, Kyi C, et al
    Management of Helicobacter pylori Infection: Myanmar Consensus Report.
    Helicobacter. 2025;30:e70090.
    >> Share

  13. LI X, Tao Y, Li H, Mai L, et al
    Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70092.
    >> Share

  14. KIM MJ, Gonzalez I, Choi NM, Graham DY, et al
    Eradication Rates of Empiric Helicobacter pylori Treatment Regimens by Race/Ethnicity in a Predominantly Immigrant U.S. Population.
    Helicobacter. 2025;30:e70095.
    >> Share

  15. JAYASEKARA H, Bassett JK, Tang HH, Peng Y, et al
    Anti-Parietal Cell Antibodies Show Differential Associations With Stomach Cancer by Site and Helicobacter pylori Status.
    Helicobacter. 2025;30:e70093.
    >> Share

  16. TISSERA K, Ramanayake A, Kim MA, Noh EJ, et al
    Expansion of cagA Copy Number in Helicobacter pylori During Co-Infection in a Mouse Model.
    Helicobacter. 2025;30:e70091.
    >> Share

  17. ZHAO WJ, Xu HM, Zhang C, Jiang XW, et al
    Host Genetic Variants Associated With Helicobacter pylori Infection: A Meta-Analysis Combined With Functional Annotation.
    Helicobacter. 2025;30:e70098.
    >> Share

  18. DUAN M, Teng T, Kong Q, Li Y, et al
    Antibiotic Combinations in Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Network Meta-Analysis.
    Helicobacter. 2025;30:e70101.
    >> Share

    September 2025
  19. SONG Z, Zuo X, Zhang Z, Wang X, et al
    Ten-Day Versus 14-Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial.
    Helicobacter. 2025;30:e70070.
    >> Share

  20. CHEN H, Wang Y, Shao Y, Su W, et al
    Multi-Omics Analysis Revealed Characterization of Gastric Microbiome and Metabolome in Helicobacter pylori-Induced Progression of MASLD.
    Helicobacter. 2025;30:e70069.
    >> Share

  21. SAVITRI CMA, Matsumoto T, Fauzia KA, Alfaray RI, et al
    Helicobacter pylori Pathogenic Factors and Their Interactions With the Gastric Microbiome.
    Helicobacter. 2025;30:e70072.
    >> Share

  22. INNS SJ, Sowerbutts S, Yumnam B, Payne K, et al
    Droplet Digital PCR-Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts Helicobacter pylori Eradication Success: A New Zealand Cohort Study.
    Helicobacter. 2025;30:e70075.
    >> Share

  23. BIBBO S, Ahlstrom G, Pes GM, Graham DY, et al
    Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults.
    Helicobacter. 2025;30:e70064.
    >> Share

  24. SUGIMOTO M, Sahara S
    Response to "Re-Evaluating the Adverse Events With the Same-Dosage Regimen in Hemodialysis Patients Undergoing Helicobacter pylori Eradication".
    Helicobacter. 2025;30:e70080.
    >> Share

  25. MISAWA K, Watanabe J, Kanno T
    Reevaluating the Adverse Events With the Same-Dosage Regimen in Hemodialysis Patients Undergoing Helicobacter pylori Eradication.
    Helicobacter. 2025;30:e70073.
    >> Share

  26. SANCHES BSF, Nyssen OP, Chaves SR, Veloso JS, et al
    Empirical Rescue Eradication Therapy for Helicobacter pylori Infection in Second and Subsequent Treatment Lines: Experience From 500 Cases of the Brazilian Registry on H. pylori Management (Hp-BrazilReg).
    Helicobacter. 2025;30:e70077.
    >> Share

  27. KITADAI Y, Takigawa H, Nagao A, Shimizu D, et al
    A Three-Way Comparison of Nodular Lesions in H. pylori-Induced Gastritis, Non-Helicobacter pylori Helicobacter (NHPH)-Induced Gastritis, and NHPH-Induced MALT Lymphoma Reveals Their Distinct Endoscopic Predictors: Distribution for Bacterial Etiology a
    Helicobacter. 2025;30:e70079.
    >> Share

  28. YAN-DONG L, Huo-Gen W, Xue-Hui Y, Xiao-Jin L, et al
    Real-Time Prediction of Helicobacter pylori Infection Using a Deep Learning Model During Esophagogastroduodenoscopy: A Prospective Multicenter Study.
    Helicobacter. 2025;30:e70078.
    >> Share

  29. SUO B, Ren X, Li C, Shi Y, et al
    Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial.
    Helicobacter. 2025;30:e70082.
    >> Share

  30. EBERHARDT KA, Schoppen S, Bindt C, Ehrhardt S, et al
    Helicobacter pylori and Impaired Early Childhood Development-Evidence From a Birth Cohort Study From Ghana and Cote d'Ivoire.
    Helicobacter. 2025;30:e70087.
    >> Share

  31. TEPES B, Denkovski M, Jurecic NB, Tepes K, et al
    Second- and Third-Line Therapies for Helicobacter pylori Eradication in Slovenia: Data From 2013-2023 of the European Registry on H. pylori Management.
    Helicobacter. 2025;30:e70085.
    >> Share

  32. ZHENG W, Zheng Z, Yang J, Nie R, et al
    Galangin Alleviates Helicobacter pylori Gastritis Through TLR2 Inhibition and Modulation of the MyD88-Dependent Inflammatory Cascades.
    Helicobacter. 2025;30:e70084.
    >> Share

  33. LASHEN SA, Shamseyea MM, Metwally RH, Abou-Farrag G, et al
    Vonoprazan-Based Triple Therapy Versus Esomeprazole-Based Triple Therapy for H. pylori Eradication in Adolescents (VONTAPE): A Randomized, Double-Blind Controlled Trial.
    Helicobacter. 2025;30:e70083.
    >> Share

    July 2025
  34. MYEONG S, Kang D, Kim JS, Cho YK, et al
    Long-Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea.
    Helicobacter. 2025;30:e70057.
    >> Share

  35. AMALIA R, Miftahussurur M, Yamaoka Y
    Response to the Letter by Guo Et al. Regarding "Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection".
    Helicobacter. 2025;30:e70055.
    >> Share

  36. YAN TL, Wang JH, Zhu RK, Zhai HL, et al
    Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial.
    Helicobacter. 2025;30:e70056.
    >> Share

  37. ZHU Y, Yang J, Fang C, Wang C, et al
    Development and Evaluation of a Multi-Epitope Vaccine Based on P22 Virus-Like Particles Targeting Helicobacter pylori.
    Helicobacter. 2025;30:e70058.
    >> Share

  38. MOON SJ, Lee AY, Hwang J, Seo JY, et al
    Helicobacter pylori Eradication in Older Individuals: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70059.
    >> Share

  39. ALIKHAN H, Levendusky J, Leonick N, Farag M, et al
    Lipidome Characterization Reveals Alterations of Fatty Acid Metabolism in Helicobacter pylori Infection.
    Helicobacter. 2025;30:e70060.
    >> Share

  40. TAO L, Qian H, Zhang L, Luo P, et al
    Optimizing Duration and Dosing Frequency of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori: A Multicenter Randomized Trial.
    Helicobacter. 2025;30:e70062.
    >> Share

  41. HOMAN M, Misak Z, Megraud F, Kori M, et al
    Helicobacter pylori Infection in Children Versus Adults, Differences in Management Guidelines: Risks and Benefits of Treatment in Childhood.
    Helicobacter. 2025;30:e70063.
    >> Share

  42. KIM HL, Kim DH, Min KW, Son BK, et al
    Arterial Stiffness and Histologically Confirmed Helicobacter pylori Infection in Young Adults.
    Helicobacter. 2025;30:e70067.
    >> Share

  43. XIANG L, Zhou Y, Guo X, Mommersteeg MC, et al
    Evaluation of Pepsinogen I, II, Gastrin 17 and Helicobacter pylori IgG in Atrophic Gastritis: A Head-To-Head Comparison of Lateral Flow and Enzyme-Linked Immunosorbent Assays.
    Helicobacter. 2025;30:e70066.
    >> Share

  44. KIM YI, Lee JY, Kim CG, Choi IJ, et al
    Helicobacter pylori Infection and Metachronous Gastric Cancer in Elderly Patients With Gastric Cancer Aged >/= 75 Years Who Underwent Endoscopic Submucosal Dissection.
    Helicobacter. 2025;30:e70068.
    >> Share

    May 2025
  45. HE X, Chen H, Chen F, Su W, et al
    Characterization of Fecal Microbial Communities in Patients With Type 2 Diabetes Mellitus Combined With Helicobacter pylori Infection.
    Helicobacter. 2025;30:e70041.
    >> Share

  46. MULDER DT, O'Mahony JF, Sun D, van Duuren LA, et al
    The Optimal Age of Helicobacter pylori Screen-and-Treat for Gastric Cancer Prevention in the United States.
    Helicobacter. 2025;30:e70039.
    >> Share

  47. YUAN H, Li Y, Wu H, Zhang J, et al
    HIF-1alpha-Induced GPR171 Expression Mediates CCL2 Secretion by Mast Cells to Promote Gastric Inflammation During Helicobacter pylori Infection.
    Helicobacter. 2025;30:e70042.
    >> Share


  48. Correction to "Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis".
    Helicobacter. 2025;30:e70044.
    >> Share

  49. REN X, Song Z
    Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Tri
    Helicobacter. 2025;30:e70043.
    >> Share

  50. CHO YS, Kim SM, Kang SH, Moon HS, et al
    Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori: A Multicenter, Prospective, and Randomized Study.
    Helicobacter. 2025;30:e70040.
    >> Share

  51. WANG Y, Zhou K, Zhang Y, Li C, et al
    The Systemic Impact of Helicobacter pylori Infection on the Microbiome of Whole Digestive Tract Based on Mucosal, Gastric Juice, and Fecal Specimens.
    Helicobacter. 2025;30:e70047.
    >> Share

  52. DU RC, Zhu YC, Xiao YT, Yang BN, et al
    Assessing the Capabilities of Novel Open-Source Artificial Intelligence-DeepSeek in Helicobacter pylori-Related Queries.
    Helicobacter. 2025;30:e70045.
    >> Share

  53. KASHYAP D, Bagde PH, Singh S, Varshney N, et al
    Gankyrin Inhibition Can Control Helicobacter pylori Generated Gastric Cancer Using In Vivo Xenograft Models.
    Helicobacter. 2025;30:e70046.
    >> Share

  54. ISHIBASHI F, Ichita C, Takasu A, Li R, et al
    The Increasing Trend of the Generational Helicobacter pylori-Naive Prevalence Among Japanese Individuals Born Between 1925 and 2015: A Systematic Review and Meta-Regression Analysis.
    Helicobacter. 2025;30:e70052.
    >> Share

  55. PENG R, Cai P, Zhang Z, Lv S, et al
    Efficacy of Three Amoxicillin Doses in Vonoprazan Dual Therapy for Helicobacter pylori Eradication: A Randomized Noninferiority Trial.
    Helicobacter. 2025;30:e70050.
    >> Share

  56. YU Z, Shen W, Lou G, Li Y, et al
    Authors' Reply to the Letter on "Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicent
    Helicobacter. 2025;30:e70049.
    >> Share

  57. SUGIMOTO M, Rimbara E, Murata M, Yamaoka Y, et al
    Roles of Gastric Non-Helicobacter pylori Helicobacter Species in Gastric Disease Development: A Review.
    Helicobacter. 2025;30:e70051.
    >> Share

  58. GUO X, Spaander MCW, Fuhler GM
    Letter to the Editor: "Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection".
    Helicobacter. 2025;30:e70053.
    >> Share

  59. MISHRA V, Dash D, Panda AK, Pathak SK, et al
    Letter to the Editor: Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis-Authors' Reply.
    Helicobacter. 2025;30:e70054.
    >> Share

    March 2025
  60. SUBSOMWONG P, Asano K, Akada J, Matsumoto T, et al
    Proteomic Profiling of Extracellular Vesicles Reveals Potential Biomarkers for Helicobacter pylori Infection and Gastric Cancer.
    Helicobacter. 2025;30:e70022.
    >> Share

  61. SU MS, Dickins B, Kiang FY, Tsai WJ, et al
    Flagellar Assembly Factor FliW2 De-Represses Helicobacter pylori FlaA-Mediated Motility by Allosteric Obstruction of Global Regulator CsrA.
    Helicobacter. 2025;30:e70019.
    >> Share

  62. FRIAS-ORDONEZ JS, Riquelme A, Marulanda-Fernandez H, Otero-Parra L, et al
    Helicobacter pylori and Colorectal Cancer: Meeting Sir Austin Bradford Hill's Causality Criteria.
    Helicobacter. 2025;30:e70024.
    >> Share

  63. ZHU M, Xu X, Cai P, Wang T, et al
    Global Population Structure, Virulence Factors and Antibiotic Resistance of Helicobacter pylori: A Pooled Analysis of 4067 Isolates From 76 Countries.
    Helicobacter. 2025;30:e70025.
    >> Share

  64. JIANG Y, Yan H, Cui J, Yang K, et al
    Artificial Intelligence in Endoscopy for Predicting Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70026.
    >> Share

  65. ZHOU BG, Li YY, Ding YB
    Letter to the Editor: "Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis".
    Helicobacter. 2025;30:e70027.
    >> Share

  66. ZHANG Y, Yan Z, Jiao Y, Feng Y, et al
    Innate Immunity in Helicobacter pylori Infection and Gastric Oncogenesis.
    Helicobacter. 2025;30:e70015.
    >> Share

  67. TEPES B, Jurecic NB, Denkovski M, Vujasinovic M, et al
    First-Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management.
    Helicobacter. 2025;30:e70029.
    >> Share

  68. KIM MJ, Je Y, Chun J, Youn YH, et al
    Helicobacter pylori Eradication Is Associated With a Reduced Risk of Metachronous Gastric Neoplasia by Restoring Immune Function in the Gastric Mucosa.
    Helicobacter. 2025;30:e70030.
    >> Share

  69. TEJEDOR-TEJADA J, Martinez-Dominguez SJ, Hernandez L, Cano-Catala A, et al
    Management of Helicobacter pylori Infection in Spain Beyond the Data Collected in the European Registry on H. pylori Management (Hp-EuReg): Results of a Nationwide Survey.
    Helicobacter. 2025;30:e70028.
    >> Share

  70. PRIADKO K, Gibaud SA, Druet A, Galmiche L, et al
    Real-Time PCR Helicobacter pylori Test in Comparison With Culture and Histology for Helicobacter pylori Detection and Identification of Resistance to Clarithromycin: A Single-Center Real-Life Study.
    Helicobacter. 2025;30:e70031.
    >> Share

  71. NAN XP, Zhao HY, Guo LN, Zheng RQ, et al
    Seven-Day Versus 14-Day Tegoprazan and Tetracycline-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Randomized, Open-Label, Noninferiority Trial.
    Helicobacter. 2025;30:e70036.
    >> Share

  72. GUTIERREZ-RAMIREZ L, Garcia-Dionisio SL, Feo-Ortega S, Gonzalez-Cervera J, et al
    The Association Between Helicobacter pylori Infection and Eosinophilic Esophagitis: Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70038.
    >> Share

  73. AMALIA R, Miftahussurur M, Syam AF, Uchida T, et al
    Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection.
    Helicobacter. 2025;30:e70035.
    >> Share

  74. LI JY, Song JC, Tian X, Liu YH, et al
    Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial.
    Helicobacter. 2025;30:e70037.
    >> Share

  75. KASTUAR S, Devalaraju S, Cifuentes JG, El-Serag HB, et al
    Impact of an Electronic Medical Record Quality Improvement Intervention on Helicobacter pylori Treatment and Eradication Rates in a U.S. Hospital System.
    Helicobacter. 2025;30:e70034.
    >> Share

  76. WANG H, Kong Q, Zhang Q, Zhang L, et al
    Efficacy and Safety of Cefuroxime-Tetracycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Penicillin-Allergic Patients: A Multicenter Randomized Controlled Trial.
    Helicobacter. 2025;30:e70033.
    >> Share

    January 2025
  77. MORI H, Nishizawa T, Morioka K, Kato M, et al
    Should Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Helicobacter. 2025;30:e70010.
    >> Share

  78. NESS A, Levi Z, Belfer RG, Dickman R, et al
    Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.
    Helicobacter. 2025;30:e70014.
    >> Share

  79. KIM Y, Lee JH, Na HK, Jung KW, et al
    Efficacy of Rifabutin-Based Helicobacter pylori Eradication Regimen in Korea With High Prevalence of Tuberculosis Infection.
    Helicobacter. 2025;30:e70011.
    >> Share

  80. HSU JY, Wu UI, Wang JT, Sheng WH, et al
    Managing Helicobacter pylori as an Infectious Disease: Implementation of Antimicrobial Stewardship.
    Helicobacter. 2025;30:e70013.
    >> Share

  81. WANG Y, Gong X, Lai Q, Fang H, et al
    The Accuracy of Melting Curve-Based Multiplex Real-Time PCR for Diagnosing Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Stool Specimens.
    Helicobacter. 2025;30:e70012.
    >> Share

  82. YU LY, Kuo YC, Lin YC, Hu KC, et al
    Interpretation the Results of Eradicating Helicobacter pylori Infection Causing Colorectal Cancer Could Be Cautious.
    Helicobacter. 2025;30:e70017.
    >> Share

  83. YU Z, Liu X, Qiao J, Shen W, et al
    Is Tailored Bismuth Quadruple Therapies (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial.
    Helicobacter. 2025;30:e70018.
    >> Share

  84. KUANG Z, Wu Y, Xie X, Zhao X, et al
    Advances in Helicobacter pylori Antimicrobial Resistance Detection: From Culture-Based to Multi-Omics-Based Technologies.
    Helicobacter. 2025;30:e70007.
    >> Share

  85. ABDUN MA, Xu L, Li XT, Mekky A, et al
    Global Prevalence of Helicobacter pylori Infection-Associated Gastric Preneoplastic Lesions in Pediatric Patients: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70021.
    >> Share

  86. GIDDINGS HJ, Teodosio A, Jones J, McMurray JL, et al
    The Gastric Microbiota Invade the Lamina Propria in Helicobacter pylori-Associated Gastritis and Precancer.
    Helicobacter. 2025;30:e70016.
    >> Share

  87. HU KY, Tseng PH, Liou JM, Tu CH, et al
    Rebound of Reflux-Related Symptoms After Helicobacter pylori Eradication in Patients With Gastroesophageal Reflux Disease: A Prospective Randomized Study.
    Helicobacter. 2025;30:e70023.
    >> Share

  88. LIU YX, Liu HN, Liu HQ, Yang YY, et al
    Vonoprazan-Amoxicillin Dual Therapy Versus Drug Sensitivity-Based Individualized Therapy as a Rescue Regimen for Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial.
    Helicobacter. 2025;30:e70009.
    >> Share

    November 2024
  89. DO TMP, Tran THT, Nguyen VT, Chu TPM, et al
    Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam.
    Helicobacter. 2024;29:e13149.
    >> Share

  90. MATSUMOTO S, Sugimoto M, Terai T, Maruyama Y, et al
    Map-Like Redness Development After Eradication Therapy for Helicobacter pylori Infection: Prospective Multicenter Observational Study.
    Helicobacter. 2024;29:e13146.
    >> Share

  91. JUNG BW, Kim YJ, Park CH
    Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices.
    Helicobacter. 2024;29:e13152.
    >> Share

  92. MASHIKO S, Ifeanyi Smith S, Rose U, Abiodun OJ, et al
    Helicobacter pylori Management in Africa: A Survey of Diagnostic, Treatment, and Related Resources.
    Helicobacter. 2024;29:e13153.
    >> Share

  93. BENITO BM, Nyssen OP, Gisbert JP
    Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First-Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta-Analysis.
    Helicobacter. 2024;29:e13148.
    >> Share

  94. LIN X, Huang H, Liu Y, Zeng Y, et al
    Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China.
    Helicobacter. 2024;29:e13151.
    >> Share

  95. OUYANG M, Zou S, Cheng Q, Shi X, et al
    Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors for First-Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta-Analysis.
    Helicobacter. 2024;29:e13150.
    >> Share

  96. LIU Q, Sadr-Azodi O, Engstrand L, Fall K, et al
    Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population-Based Nationwide Cohort Study in Sweden.
    Helicobacter. 2024;29:e70001.
    >> Share

  97. REQUENA D, Ribas E, Gilman RH, Cabrera L, et al
    Effects of High Altitude and Diet on Gastric Disease Severity in Helicobacter pylori Infection in Peru.
    Helicobacter. 2024;29:e13147.
    >> Share

  98. MANFREDI M, Ravikumara M
    Helicobacter pylori Infection in Children: To Eradicate or Not to Eradicate?
    Helicobacter. 2024;29:e70002.
    >> Share

  99. NOH JH, Choi KD, Na HK, Ahn JY, et al
    Effect of Macrolide Exposure on Tailored Helicobacter pylori Eradication Therapy and Antibiotic Resistance Profiles: A Prospective Study Using the Drug Utilization Review System.
    Helicobacter. 2024;29:e70003.
    >> Share

  100. WANG X, Chan XF, Go Y, Wang Y, et al
    Combatting Helicobacter pylori: A Focus on Nanomaterials.
    Helicobacter. 2024;29:e70004.
    >> Share

  101. MISHRA V, Dash D, Panda AK, Pathak SK, et al
    Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis.
    Helicobacter. 2024;29:e70006.
    >> Share

    September 2024
  102. LE THI TG, Werkstetter K, Kotilea K, Bontems P, et al
    Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry.
    Helicobacter. 2024;29:e13134.
    >> Share

  103. CHEUNG KS, Lyu T, Deng Z, Han S, et al
    Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Helicobacter. 2024;29:e13133.
    >> Share

  104. SUN L, Liu M, Gong Y, Zhai K, et al
    Rapid Antimicrobial Susceptibility Test of Helicobacter pylori to Metronidazole via Single-Cell Raman Spectrometry.
    Helicobacter. 2024;29:e13136.
    >> Share


  105. Correction to "Long-Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial".
    Helicobacter. 2024;29:e13127.
    >> Share

  106. LIU N, Luo Q, Gou L, Shen X, et al
    Knowledge and Practices of Helicobacter pylori Infection Management Among Physicians in Gansu Province, China: A Cross-Sectional Study.
    Helicobacter. 2024;29:e13137.
    >> Share

  107. HUANG Y, Qiu S, Guo Y, Chen J, et al
    Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study.
    Helicobacter. 2024;29:e13138.
    >> Share

  108. BOTIJA G, Galicia G, Martinez B, Cuadrado C, et al
    Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children-Data From the RENIHp Registry.
    Helicobacter. 2024;29:e13142.
    >> Share

  109. REUM CHOE A, Tae CH, Choi M, Shim KN, et al
    Systematic Review and Meta-Analysis: Bismuth Enhances the Efficacy for Eradication of Helicobacter pylori.
    Helicobacter. 2024;29:e13141.
    >> Share

  110. WANG Z, Hu Y, Fei R, Han W, et al
    Tracking the Helicobacter pylori Epidemic in Adults and Children in China.
    Helicobacter. 2024;29:e13139.
    >> Share

  111. DUAN M, Kong Q, Wang H, Li Y, et al
    Optimal Duration of Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Helicobacter. 2024;29:e13144.
    >> Share

  112. LAI J, Angulmaduwa S, Kim MA, Kim A, et al
    Influence of oipA Phase Variation on Virulence Phenotypes Related to Type IV Secretion System in Helicobacter pylori.
    Helicobacter. 2024;29:e13140.
    >> Share

  113. LEE JW, Kim N, Lee J, Jo SY, et al
    Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiar
    Helicobacter. 2024;29:e13143.
    >> Share


  114. Correction to Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008-2023): A Systematic Review.
    Helicobacter. 2024;29:e13145.
    >> Share

    July 2024
  115. LI B, He J, Zhang R, Liu S, et al
    Integrin-Linked Kinase in the Development of Gastric Tumors Induced by Helicobacter pylori: Regulation and Prevention Potential.
    Helicobacter. 2024;29:e13109.
    >> Share

  116. LI XT, Xu L, Zhang C, Qi YB, et al
    Improved Patient Adherence to Family-Based Helicobacter pylori Infection Control and Management Strategy in Central China and Its Influencing Factors.
    Helicobacter. 2024;29:e13114.
    >> Share

  117. JAUVAIN M, Lepied G, Benejat L, Roudier N, et al
    Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13108.
    >> Share

  118. MARTINEZ-DOMINGUEZ SJ, Nyssen OP, Lanas A, Alfaro E, et al
    Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
    Helicobacter. 2024;29:e13111.
    >> Share

  119. CABRERA C, Torres J, Serrano CA, Gallardo P, et al
    Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008-2023): A Systematic Review.
    Helicobacter. 2024;29:e13101.
    >> Share

  120. ZHAO JT, Zhang Y, Wang XW, Zou PY, et al
    Long-term effects of fecal microbiota transplantation on gut microbiota after Helicobacter pylori eradication with bismuth quadruple therapy: A randomized controlled trial.
    Helicobacter. 2024;29:e13079.
    >> Share

  121. QIU S, Huang Y, Chen J, Guo Y, et al
    Vonoprazan-Amoxicillin Dual Therapy With Different Amoxicillin Administration Regimens for Helicobacter pylori Treatment: A Randomized Controlled Trial.
    Helicobacter. 2024;29:e13118.
    >> Share

  122. DORE MP, Hernaez R, Graham DY
    Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data.
    Helicobacter. 2024;29:e13112.
    >> Share

  123. HU Y, Lai Y, Liao F, Shu X, et al
    Assessing Accuracy of ChatGPT on Addressing Helicobacter pylori Infection-Related Questions: A National Survey and Comparative Study.
    Helicobacter. 2024;29:e13116.
    >> Share

  124. MELNIK P, Weintraub I, Shamaly H, Cohen S, et al
    Helicobacter pylori-Associated Extranodal Marginal Zone Lymphoma of Mucosa-Associated Tissue in Children: A Multicenter Case Series.
    Helicobacter. 2024;29:e13113.
    >> Share

  125. MA Y, Zhou X, Liu Y, Xu S, et al
    An Economic Evaluation of Family-Based Versus Traditional Helicobacter pylori Screen-and-Treat Strategy: Based on Real-World Data and Microsimulation Model.
    Helicobacter. 2024;29:e13123.
    >> Share


  126. Correction to Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
    Helicobacter. 2024;29:e13124.
    >> Share

  127. LIU Z, Li H, Huang X, Liu Q, et al
    Animal Models of Helicobacter pylori Infection and Vaccines: Current Status and Future Prospects.
    Helicobacter. 2024;29:e13119.
    >> Share

  128. ZHOU S, Zheng Z, Wang L, Song W, et al
    Correlation of FUT3 and FUT6 Gene Polymorphisms With Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13122.
    >> Share

  129. ZENG S, Kong Q, Wu X, Ma T, et al
    Artificial Intelligence-Generated Patient Education Materials for Helicobacter pylori Infection: A Comparative Analysis.
    Helicobacter. 2024;29:e13115.
    >> Share

  130. DING YM, Zhang QM, Li RL, Han ZX, et al
    Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Helicobacter. 2024;29:e13121.
    >> Share

  131. YANG P, Jiang J
    Letter to the Editor Regarding the Article: "Exploring the Capacities of ChatGPT: A Comprehensive Evaluation of Its Accuracy and Repeatability in Addressing Helicobacter pylori-Related Queries".
    Helicobacter. 2024;29:e13131.
    >> Share

  132. KIM JS, Kim BW, Kim JI, Chung WC, et al
    Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K-CREATE Study.
    Helicobacter. 2024;29:e13126.
    >> Share

  133. KOWADA A
    Cost-Effectiveness of Population-Based Helicobacter pylori Screening With Eradication for Optimal Age of Implementation.
    Helicobacter. 2024;29:e13120.
    >> Share

  134. ZHANG Z, Cui M, Ji X, Su G, et al
    Candidate Antigens and the Development of Helicobacter pylori Vaccines.
    Helicobacter. 2024;29:e13128.
    >> Share

  135. CHIU YT, Lee FJ, Kuo CY, Chen YT, et al
    Seven-Day Vonoprazan-Based Triple Therapy as First-Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial.
    Helicobacter. 2024;29:e13129.
    >> Share

  136. XIA C, Chen Z, Chen Y, Wei F, et al
    Effects of Latilactobacillus sakei LZ217 on Gastric Mucosal Colonization, Metabolic Interference, and Urease Expression in Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13130.
    >> Share

  137. IWATA E, Sugimoto M, Asaoka D, Hojo M, et al
    Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study.
    Helicobacter. 2024;29:e13125.
    >> Share

    May 2024
  138. JUNG K, Jee SR, Lee MW, Koh M, et al
    Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
    Helicobacter. 2024;29:e13084.
    >> Share

  139. KAOUAH Z, Buyck JM, Pichon M, Burucoa C, et al
    In vitro efficacy of combinations of antibiotics used in clinical practice on clinical isolates of Helicobacter pylori.
    Helicobacter. 2024;29:e13081.
    >> Share

  140. ARFI S, Sharma P, Kumar M, Mehra S, et al
    Antibiotic susceptibility pattern of Helicobacter pylori against eight antibiotics: A study from North India.
    Helicobacter. 2024;29:e13093.
    >> Share

  141. XIE J, Peng J, Liu D, Zeng R, et al
    Treatment failure is a key factor in the development of Helicobacter pylori resistance.
    Helicobacter. 2024;29:e13091.
    >> Share

  142. TALAYEV V, Svetlova M, Zaichenko I, Voronina E, et al
    CCR6(+) T helper cells and regulatory T cells in the blood and gastric mucosa during Helicobacter pylori infection.
    Helicobacter. 2024;29:e13097.
    >> Share

  143. KAYAMBA V, Munshi H, Hankolwe MN, Kaluba Kavimba C, et al
    Nationwide survey of Helicobacter pylori seropositivity and gastric atrophy in Zambia.
    Helicobacter. 2024;29:e13096.
    >> Share

  144. KOTILEA K, Romano C, Miele E, Kindermann A, et al
    Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study.
    Helicobacter. 2024;29:e13092.
    >> Share

  145. ZHANG C, Qi YB, Hu RB, Xu L, et al
    Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
    Helicobacter. 2024;29:e13063.
    >> Share

  146. HAN Z, Zhang Q, Mirza IA, Ding Y, et al
    Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Helicobacter. 2024;29:e13102.
    >> Share

  147. YU J, He Y, Yao W, Liu T, et al
    Helicobacter pylori CagA Promotes the Formation of Gallstones by Increasing the Permeability of Gallbladder Epithelial Cells.
    Helicobacter. 2024;29:e13100.
    >> Share

  148. LAI Y, Liao F, Zhao J, Zhu C, et al
    Exploring the capacities of ChatGPT: A comprehensive evaluation of its accuracy and repeatability in addressing helicobacter pylori-related queries.
    Helicobacter. 2024;29:e13078.
    >> Share

  149. KONG Q, Mirza IA, Zhang X, Song X, et al
    Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.
    Helicobacter. 2024;29:e13098.
    >> Share

  150. YU Y, Xue J, Lin F, Liu D, et al
    Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta-Analysis.
    Helicobacter. 2024;29:e13103.
    >> Share

  151. JAFARZADEH A, Jafarzadeh Z, Nemati M, Yoshimura A, et al
    The Interplay Between Helicobacter pylori and Suppressors of Cytokine Signaling (SOCS) Molecules in the Development of Gastric Cancer and Induction of Immune Response.
    Helicobacter. 2024;29:e13105.
    >> Share

  152. MOGES ESKEZIYAW B, Waihenya R, Maina N, Muuo Nzou S, et al
    Immunoinformatics-Based Designing of Novel and Potent Multi-Epitope PSA D15 and Cag11 Immunogens for Helicobacter pylori Immunodiagnostic Assay Development.
    Helicobacter. 2024;29:e13104.
    >> Share

  153. DORE MP, Meloni G, Bassu I, Pes GM, et al
    Helicobacter pylori Infection Does Not Protect Against Allergic Diseases: Evidence From a Pediatric Cohort From Northern Sardinia, Italy.
    Helicobacter. 2024;29:e13107.
    >> Share

  154. SAHARA S, Sugimoto M, Murata M, Iwata E, et al
    Eradication Therapy for Helicobacter pylori Infection in Patients Receiving Hemodialysis: Review.
    Helicobacter. 2024;29:e13106.
    >> Share

    March 2024
  155. YANG H, Zhang M, Ma G, Yang J, et al
    Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
    Helicobacter. 2024;29:e13059.
    >> Share

  156. CHEN S, Zhao H, Tian Y, Wu Q, et al
    Antagonizing roles of SHP1 in the pathogenesis of Helicobacter pylori infection.
    Helicobacter. 2024;29:e13066.
    >> Share

  157. VANGRAVS R, Mezmale L, Slefarska-Wolak D, Dauss E, et al
    Volatilomic signatures of different strains of Helicobacter pylori.
    Helicobacter. 2024;29:e13064.
    >> Share

  158. TSUDA M, Watanabe Y, Oikawa R, Watanabe R, et al
    Impact of mixed-infection rate of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains on the success rate of clarithromycin-based eradication treatment.
    Helicobacter. 2024;29:e13062.
    >> Share

  159. APOORVA E, Jacob R, Rao DN, Kumar S, et al
    Helicobacter pylori enhances HLA-C expression in the human gastric adenocarcinoma cells AGS and can protect them from the cytotoxicity of natural killer cells.
    Helicobacter. 2024;29:e13069.
    >> Share

  160. PEYPAR MH, Yeganeh AV, Ramazani A, Alizadeh A, et al
    Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review.
    Helicobacter. 2024;29:e13067.
    >> Share

  161. OKAMURA T, Iwaya Y, Nagaya T, Horiuchi K, et al
    Diagnosis by combination of endoscopic findings helps differentiate non-Helicobacter pylori Helicobacter-infected gastritis from Helicobacter pylori-infected gastritis.
    Helicobacter. 2024;29:e13070.
    >> Share

  162. LUO Q, Liu C, Zhang A, Zhang D, et al
    Research progress in photodynamic therapy for Helicobacter pylori infection.
    Helicobacter. 2024;29:e13068.
    >> Share

  163. MI C, Suo B, Tian X, Wang Y, et al
    Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.
    Helicobacter. 2024;29:e13073.
    >> Share

  164. LARA ICAZA JD, Tapia RL, Triana CTC, Ramirez LCR, et al
    Refractoriness to anti-Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil-Ecuador.
    Helicobacter. 2024;29:e13060.
    >> Share

  165. LIU J, Jia J, Shi T, Bai Y, et al
    Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target.
    Helicobacter. 2024;29:e13075.
    >> Share

  166. MOFIDIFAR S, Yadegar A, Karimi-Jafari MH
    A reconstructed genome-scale metabolic model of Helicobacter pylori for predicting putative drug targets in clarithromycin and rifampicin resistance conditions.
    Helicobacter. 2024;29:e13074.
    >> Share

  167. GUAN X, Ning J, Fu W, Wang Y, et al
    Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-kappaB/IL8 pathway.
    Helicobacter. 2024;29:e13072.
    >> Share

  168. CHEN J, Zhang Y, Min H, Zhi J, et al
    Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Helicobacter. 2024;29:e13077.
    >> Share

  169. AMIOT A, Hacoon J, Heluwaert F, Mion F, et al
    14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
    Helicobacter. 2024;29:e13076.
    >> Share

  170. STERBENC A, Godnov U, Vodicar PM, Simcic S, et al
    Prevalence of Helicobacter pylori infection among Slovenian children and adolescents: A prospective cohort study.
    Helicobacter. 2024;29:e13082.
    >> Share

  171. KATO M, Ono S, Kawada K, Dohi O, et al
    Diagnostic performance of linked color imaging for gastric cancer by Helicobacter pylori infection status: A subanalysis of the large-scale, multicenter randomized controlled trial LCI-FIND.
    Helicobacter. 2024;29:e13080.
    >> Share

  172. AGAWA H, Tsukadaira T, Kobayashi N, Kodaira H, et al
    Four cases of non-Helicobacter pylori Helicobacter-infected gastritis with duodenal spiral bacilli.
    Helicobacter. 2024;29:e13083.
    >> Share

    January 2024
  173. VON MUHLENBROCK C, Cordova A, Nunez P, Pacheco N, et al
    Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: Experience from University Hospital in Chile.
    Helicobacter. 2024;29:e13052.
    >> Share

  174. MARZHOSEYNI Z, Mousavi MJ, Ghotloo S
    Helicobacter pylori antigens as immunomodulators of immune system.
    Helicobacter. 2024;29:e13058.
    >> Share

  175. DUTTA S, Jain S, Das K, Verma P, et al
    Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review.
    Helicobacter. 2024;29:e13057.
    >> Share

  176. TIRGAR FAKHERI S, Shokri-Afra H, Graham DY, Bari Z, et al
    A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran.
    Helicobacter. 2024;29:e13061.
    >> Share

  177. LO HY, Yang YJ
    Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan-A 20-year longitudinal follow-up.
    Helicobacter. 2024;29:e13049.
    >> Share

  178. WU X, Duan M, Kong Q, Zeng S, et al
    Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review.
    Helicobacter. 2024;29:e13048.
    >> Share

  179. JU KP, Kong QZ, Li YY, Li YQ, et al
    Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Helicobacter. 2024;29:e13054.
    >> Share

  180. MATSUMOTO S, Sugimoto M, Fukuzawa M, Uesugi N, et al
    Risk of map-like redness development after eradication therapy for Helicobacter pylori infection.
    Helicobacter. 2024;29:e13046.
    >> Share

  181. KONG QZ, Ju KP, Wan M, Liu J, et al
    Comparative analysis of large language models in medical counseling: A focus on Helicobacter pylori infection.
    Helicobacter. 2024;29:e13055.
    >> Share

  182. HU Y, Huang XH, Zhou B, Liu ML, et al
    Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Helicobacter. 2024;29:e13045.
    >> Share

    November 2023
  183. DU RC, Hu YX, Ouyang Y, Ling LX, et al
    Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Helicobacter. 2023 Nov 30:e13039. doi: 10.1111/hel.13039.
    >> Share

  184. LIANG Y, Yang Y, Nong R, Huang H, et al
    Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication?
    Helicobacter. 2023 Nov 29:e13042. doi: 10.1111/hel.13042.
    >> Share

  185. FENG Y, Huang Q, Luo M, Wei J, et al
    The association between Helicobacter pylori and gastrointestinal disorders during pregnancy: A Multicenter retrospective study.
    Helicobacter. 2023 Nov 27:e13032. doi: 10.1111/hel.13032.
    >> Share

  186. MELO J, Cavadas B, Pereira L, Figueiredo C, et al
    Transcriptomic remodeling of gastric cells by Helicobacter pylori outer membrane vesicles.
    Helicobacter. 2023 Nov 23:e13031. doi: 10.1111/hel.13031.
    >> Share

  187. LIM NR, Kim J, Chung WC
    Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients.
    Helicobacter. 2023 Nov 20:e13036. doi: 10.1111/hel.13036.
    >> Share

  188. XU W, Yang B, Lin L, Lin Q, et al
    Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter study from 2016 to 2023.
    Helicobacter. 2023 Nov 20:e13038. doi: 10.1111/hel.13038.
    >> Share

  189. ZHOU BG, Jiang X, Ding YB, She Q, et al
    Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Helicobacter. 2023 Nov 20:e13040. doi: 10.1111/hel.13040.
    >> Share

  190. VERNON-ROBERTS A, Premaratne M, Wright R, Keenan JI, et al
    Profile of Helicobacter pylori infections among children in the South Island of New Zealand (2010-2021).
    Helicobacter. 2023 Nov 20:e13037. doi: 10.1111/hel.13037.
    >> Share

  191. YUNLE K, Tong W, Jiyang L, Guojun W, et al
    Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants-A review.
    Helicobacter. 2023 Nov 16:e13034. doi: 10.1111/hel.13034.
    >> Share

  192. FANI T, Ioannis TG
    Letter to the Editor regarding the article: "Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy".
    Helicobacter. 2023 Nov 13:e13035. doi: 10.1111/hel.13035.
    >> Share

  193. LEE CT, Wu CT, Chang WL, Yang EH, et al
    The nonadherence and risk factors of eradication failure by sequential therapy as first-line anti-Helicobacter pylori treatment in real-world clinical practice.
    Helicobacter. 2023 Nov 10:e13033. doi: 10.1111/hel.13033.
    >> Share

    October 2023
  194. YE J, Feng T, Su L, Li J, et al
    Interactions between Helicobacter pylori infection and host metabolic homeostasis: A comprehensive review.
    Helicobacter. 2023 Oct 23:e13030. doi: 10.1111/hel.13030.
    >> Share

  195. YOUSEFI M, Rezaei S, Khoshbaten M, Sarmasti M, et al
    Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
    Helicobacter. 2023 Oct 15:e13027. doi: 10.1111/hel.13027.
    >> Share

  196. GAO W, Zhu M, Yin Y, Zhang X, et al
    Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
    Helicobacter. 2023 Oct 15:e13022. doi: 10.1111/hel.13022.
    >> Share

  197. TAN W, Liu Y, Shi Z, Zheng B, et al
    Information quality of videos related to Helicobacter pylori infection on TikTok: Cross-sectional study.
    Helicobacter. 2023 Oct 12:e13029. doi: 10.1111/hel.13029.
    >> Share

  198. OKIMOTO T, Ando T, Sasaki M, Ono S, et al
    Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018-2020.
    Helicobacter. 2023 Oct 12:e13028. doi: 10.1111/hel.13028.
    >> Share

  199. O'CONNOR HJ
    Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy.
    Helicobacter. 2023 Oct 11:e13026. doi: 10.1111/hel.13026.
    >> Share

  200. WU S, Chen Y, Chen Z, Wei F, et al
    Reactive oxygen species and gastric carcinogenesis: The complex interaction between Helicobacter pylori and host.
    Helicobacter. 2023 Oct 5:e13024. doi: 10.1111/hel.13024.
    >> Share

  201. DORE MP, Erre GL, Piroddu J, Pes GM, et al
    Helicobacter pylori infection and rheumatoid arthritis as risk enhancers' factors for atherosclerotic cardiovascular diseases.
    Helicobacter. 2023 Oct 4:e13025. doi: 10.1111/hel.13025.
    >> Share

    September 2023
  202. VESGA FJ, Beltran-Benavides AR, Marquez-Duque AM, Venegas C, et al
    Helicobacter pylori virulence genotypes in Bogota River and wastewater treatment plants in Colombia.
    Helicobacter. 2023 Sep 27:e13023. doi: 10.1111/hel.13023.
    >> Share

  203. RATANA-AMORNPIN S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, et al
    Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
    Helicobacter. 2023 Sep 18:e13019. doi: 10.1111/hel.13019.
    >> Share

  204. LI Y, Ouyang Y, He C
    Research trends on the relationship between Helicobacter pylori and microbiota: A bibliometric analysis.
    Helicobacter. 2023 Sep 11:e13021. doi: 10.1111/hel.13021.
    >> Share

  205. ZHANG X, Zhang K, Yan L, Wang P, et al
    The role of toll-like receptors in immune tolerance induced by Helicobacter pylori infection.
    Helicobacter. 2023 Sep 10:e13020. doi: 10.1111/hel.13020.
    >> Share

  206. GONG X, Shen L, Xie J, Liu D, et al
    Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis.
    Helicobacter. 2023 Sep 3:e13011. doi: 10.1111/hel.13011.
    >> Share

    August 2023
  207. LIN K, Huang L, Wang Y, Li K, et al
    Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
    Helicobacter. 2023 Aug 27:e13015. doi: 10.1111/hel.13015.
    >> Share

  208. QUACH DT, Vilaichone RK, Luu MN, Lee YY, et al
    Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
    Helicobacter. 2023 Aug 27:e13018. doi: 10.1111/hel.13018.
    >> Share

  209. YU Z, Zhang X, Zhao Q, Yan X, et al
    Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
    Helicobacter. 2023 Aug 25:e13016. doi: 10.1111/hel.13016.
    >> Share

  210. ISMAIL NI, Nawawi KNM, Hsin DCC, Hao KW, et al
    Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
    Helicobacter. 2023 Aug 23:e13017. doi: 10.1111/hel.13017.
    >> Share

  211. ZHU F, Zhang X, Li P, Zhu Y, et al
    Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis.
    Helicobacter. 2023 Aug 21:e13013. doi: 10.1111/hel.13013.
    >> Share

  212. SU NY, Shi Q, Mei H, Hu J, et al
    Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
    Helicobacter. 2023 Aug 10:e13003. doi: 10.1111/hel.13003.
    >> Share

  213. BAWAND R, Ghiasian M, Samadyan M, Qaderi S, et al
    Association of Helicobacter pylori with migraine headaches and the effects of this infection and its eradication on the migraine characteristics in adults: A comprehensive systematic review and meta-analysis.
    Helicobacter. 2023 Aug 2:e13010. doi: 10.1111/hel.13010.
    >> Share

    July 2023
  214. DU RC, Ouyang YB, Lu NH, Hu Y, et al
    Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Helicobacter. 2023 Jul 29:e13012. doi: 10.1111/hel.13012.
    >> Share

  215. NGUYEN TC, Le GKN, Pham DTH, Pham BV, et al
    Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study.
    Helicobacter. 2023 Jul 27:e13009. doi: 10.1111/hel.13009.
    >> Share

  216. LIMA IS, da Silva TM, Weiss S, Homuth G, et al
    Genome-wide association study of Helicobacter pylori serological status in Latin American children.
    Helicobacter. 2023 Jul 27:e13008. doi: 10.1111/hel.13008.
    >> Share

  217. DU RC, Zhang Y, Wang MH, Lu NH, et al
    TikTok and Bilibili as sources of information on Helicobacter pylori in China: A content and quality analysis.
    Helicobacter. 2023 Jul 15:e13007. doi: 10.1111/hel.13007.
    >> Share

  218. KOTILEA K, Iliadis E, Nguyen J, Salame A, et al
    Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
    Helicobacter. 2023 Jul 4:e13006. doi: 10.1111/hel.13006.
    >> Share

    June 2023
  219. HASSAN SS, Nader M, Nagy M, Mohamed M, et al
    Antimicrobial screening involving Helicobacter pylori of nano-therapeutic compounds based on the amoxicillin antibiotic drug.
    Helicobacter. 2023 Jun 30:e13004. doi: 10.1111/hel.13004.
    >> Share

  220. ZHANG Y, Zhao Z, Fu W, Ding S, et al
    The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.
    Helicobacter. 2023 Jun 29:e12999. doi: 10.1111/hel.12999.
    >> Share

  221. ZHANG Z, Chen X, Li B, Xia T, et al
    Helicobacter pylori induces urease subunit B-specific CD8(+) T cell responses in infected individuals via cytosolic pathway of cross-presentation.
    Helicobacter. 2023 Jun 29:e13005. doi: 10.1111/hel.13005.
    >> Share

  222. BARREYRO FJ, Maiorana F, Caronia MV, Elizondo K, et al
    Association between genetic polymorphisms of NOD1, Interleukin-1B, and cagA strain with low-grade duodenal eosinophilia in Helicobacter pylori-related dyspepsia.
    Helicobacter. 2023 Jun 23:e13002. doi: 10.1111/hel.13002.
    >> Share

  223. ISMAIL M, Majaliwa ND, Vale FF, Cumbana R, et al
    Molecular detection of Helicobacter pylori and its genotypic antimicrobial resistance patterns in dyspeptic Mozambican patients.
    Helicobacter. 2023 Jun 20:e13000. doi: 10.1111/hel.13000.
    >> Share

  224. KATSANDE PM, Nguyen VD, Nguyen TLP, Nguyen TKC, et al
    Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines.
    Helicobacter. 2023 Jun 14:e12997. doi: 10.1111/hel.12997.
    >> Share

  225. LEE SY, Kim JH, Sung IK, Park HS, et al
    Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
    Helicobacter. 2023 Jun 9:e12998. doi: 10.1111/hel.12998.
    >> Share

    May 2023
  226. JIANG F, Ju C, Guo CG, Cheung KS, et al
    Risk of hospitalization for upper gastrointestinal bleeding in Helicobacter pylori eradicated patients newly started on warfarin or direct oral anticoagulants: A population-based cohort study.
    Helicobacter. 2023 May 29:e12990. doi: 10.1111/hel.12990.
    >> Share

  227. ZENG R, Li X, Wang F, Xie J, et al
    Reinforced medication adherence improves Helicobacter pylori eradication rate in developing countries: A systematic review and meta-analysis of randomized controlled trials.
    Helicobacter. 2023 May 17:e12989. doi: 10.1111/hel.12989.
    >> Share

  228. HU J, Mei H, Su NY, Sun WJ, et al
    Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Helicobacter. 2023 May 9:e12970. doi: 10.1111/hel.12970.
    >> Share

  229. KARAYIANNIS I, Martinez-Gonzalez B, Kontizas E, Kokkota AV, et al
    Induction of MMP-3 and MMP-9 expression during Helicobacter pylori infection via MAPK signaling pathways.
    Helicobacter. 2023 May 4:e12987. doi: 10.1111/hel.12987.
    >> Share

  230. WANG R, Huang S, Gan P, Pan X, et al
    States and hotspots in Helicobacter pylori research from 2002 to 2021: A bibliometric analysis.
    Helicobacter. 2023 May 3:e12986. doi: 10.1111/hel.12986.
    >> Share

    April 2023
  231. MCNULTY CAM
    The first 5 years of Helicobacter pylori research-With an emphasis on the United Kingdom.
    Helicobacter. 2023 Apr 27:e12982. doi: 10.1111/hel.12982.
    >> Share

  232. LI M, Gao N, Wang S, Guo Y, et al
    Bibliometric analysis of Helicobacter pylori resistance-from 2002 to 2022.
    Helicobacter. 2023 Apr 27:e12983. doi: 10.1111/hel.12983.
    >> Share

  233. ZANG H, Wang J, Wang H, Guo J, et al
    Metabolic alterations in patients with Helicobacter pylori-related gastritis: The H. pylori-gut microbiota-metabolism axis in progression of the chronic inflammation in the gastric mucosa.
    Helicobacter. 2023 Apr 25:e12984. doi: 10.1111/hel.12984.
    >> Share

  234. KIM JS, Ko W, Chung JW, Kim TH, et al
    Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
    Helicobacter. 2023 Apr 21:e12977. doi: 10.1111/hel.12977.
    >> Share

  235. HAN X, Yu X, Gao X, Wang X, et al
    Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
    Helicobacter. 2023 Apr 17:e12985. doi: 10.1111/hel.12985.
    >> Share

  236. HU S, Zhou Y, Deng Y, Bo Y, et al
    Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.
    Helicobacter. 2023 Apr 11:e12960. doi: 10.1111/hel.12960.
    >> Share

  237. SOH H, Kim N, Moon J, Lee HM, et al
    Gastric mucosal swab as an alternative to biopsy for Helicobacter pylori detection.
    Helicobacter. 2023 Apr 7:e12980. doi: 10.1111/hel.12980.
    >> Share

  238. YU H, Li J, Liu X, Chen Z, et al
    Helicobacter pylori bacteremia presenting as seizure and unconsciousness: The brief case.
    Helicobacter. 2023 Apr 5:e12973. doi: 10.1111/hel.12973.
    >> Share

  239. ZENG R, Xie Y
    Inquiry about methodology used to isolate multiple Helicobacter pylori strains from the same patient.
    Helicobacter. 2023 Apr 3:e12981. doi: 10.1111/hel.12981.
    >> Share

  240. KOSUNEN TU, Nieminen AA, Kokkola A, Arkkila P, et al
    Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study.
    Helicobacter. 2023 Apr 3:e12979. doi: 10.1111/hel.12979.
    >> Share

  241. COLLIN A, Mion F, Kefleyesus A, Beets C, et al
    Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia.
    Helicobacter. 2023;28:e12952.
    >> Share

    March 2023
  242. XIE Y, Hu Y, Zhu Y, Wang H, et al
    Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
    Helicobacter. 2023 Mar 31:e12978. doi: 10.1111/hel.12978.
    >> Share

  243. KWON YM, Kim SJ, Lee JG, Lee SP, et al
    Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori.
    Helicobacter. 2023 Mar 28:e12974. doi: 10.1111/hel.12974.
    >> Share

  244. SUN L, Zheng H, Qiu M, Hao S, et al
    Helicobacter pylori infection and risk of cardiovascular disease.
    Helicobacter. 2023 Mar 28:e12967. doi: 10.1111/hel.12967.
    >> Share

  245. LYU T, Cheung KS, Deng Z, Ni L, et al
    Whole genome sequencing reveals novel genetic mutations of Helicobacter pylori associating with resistance to clarithromycin and levofloxacin.
    Helicobacter. 2023 Mar 25:e12972. doi: 10.1111/hel.12972.
    >> Share

  246. IKEDA N, Shoji H, Ikuse T, Ohkawa N, et al
    A case of neonatal thrombocytopenia due to maternal Helicobacter pylori-associated immune thrombocytopenia.
    Helicobacter. 2023 Mar 23:e12976. doi: 10.1111/hel.12976.
    >> Share

  247. KIM SB, Kim N, Park J, Hwang IC, et al
    Preventive effect of Helicobacter pylori eradication on the coronary heart diseases depending on age and sex with a median follow-up of 51 months.
    Helicobacter. 2023 Mar 22:e12969. doi: 10.1111/hel.12969.
    >> Share

  248. ERGENC M, Uprak TK
    YouTube as a source of information on Helicobacter pylori: Content and quality analysis.
    Helicobacter. 2023 Mar 21:e12971. doi: 10.1111/hel.12971.
    >> Share

  249. SHENG C, Sun L, Lyu Z, Li L, et al
    Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.
    Helicobacter. 2023 Mar 20:e12966. doi: 10.1111/hel.12966.
    >> Share

  250. ANTUNES R, Oleastro M, Nogueira JP, Lopes AI, et al
    Time trend prevalence of helicobacter pylori infection and endoscopic findings in symptomatic children in Portugal: A retrospective study based on three time points in 2009, 2014, and 2019.
    Helicobacter. 2023 Mar 10:e12963. doi: 10.1111/hel.12963.
    >> Share

  251. YU T, Lu T, Deng W, Yao D, et al
    Microbiome and function alterations in the gastric mucosa of asymptomatic patients with Helicobacter pylori infection.
    Helicobacter. 2023 Mar 8:e12965. doi: 10.1111/hel.12965.
    >> Share

    February 2023
  252. REN X, Shi Y, Suo B, Yao X, et al
    Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysis.
    Helicobacter. 2023 Feb 24:e12958. doi: 10.1111/hel.12958.
    >> Share

  253. KAJIHARA Y, Shimoyama T, Mizuki I
    Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing.
    Helicobacter. 2023 Feb 24:e12961. doi: 10.1111/hel.12961.
    >> Share

  254. ARINO-PEREZ I, Martinez-Dominguez SJ, Alfaro Almajano E, Carrera-Lasfuentes P, et al
    Mistakes in the diagnosis and treatment of Helicobacter pylori infection in daily clinical practice.
    Helicobacter. 2023 Feb 24:e12957. doi: 10.1111/hel.12957.
    >> Share

  255. HE T, Zhang F, Zhang J, Wei S, et al
    UreB immunodominant epitope-specific CD8(+) T-cell responses were beneficial in reducing gastric symptoms in Helicobacter pylori-infected individuals.
    Helicobacter. 2023 Feb 24:e12959. doi: 10.1111/hel.12959.
    >> Share

  256. MACEDO SILVA V, Lima Capela T, Freitas M, Boal Carvalho P, et al
    A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Helicobacter. 2023 Feb 24:e12962. doi: 10.1111/hel.12962.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016